Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial

Por Nobuaki Kobayashi, Hisashi Hashimoto, Chisato Kamimaki, Ryo Nagasawa, Katsushi Tanaka, Sousuke Kubo, Seigo Katakura, Hao Chen, Nobuyuki Hirama, Ryota Ushio, Ayako Aoki, Kentaro Nakashima, Shuhei Teranishi, Saki Manabe, Hiroki Watanabe, Nobuyuki Horita, Keisuke Watanabe, Yu Hara, Masaki Yamamoto, Makoto Kudo, Hongmei Piao, Takeshi Kaneko
Publicado em 2020-08-01